Updated on 9 May 2012
On the factors that led to the development of the product, Dr Manu Chaudhary, director, research and joint managing director, Venus Remedies, says, "Our company, as an R&D strategy, practices the concept of translational medicine, which is bed-to-benchside and return. The drawbacks of the currently available regimes in the acute-to-chronic pain management were evaluated in depth, and with that conception a product was formulated which could surmount the ascertained fallacies. This was how the notion of Achnil came into existence. Envisaging, the existence of huge unmet medical needs in terms of a safe, efficacious and long acting drug for pain management, the innovative product Achnil is able to cater to all the needs."
Venus has secured patents from India as well as from Europe for Achnil, which are valid till 2025. It plans to launch Achnil in other markets worldwide including major European economies such as Germany, UK, France, Spain, Sweden, Italy and Switzerland. The US represents the largest regional market for pain management worldwide, followed by Europe, as stated by a new market research report on pain management. Increasing aging population worldwide, growing number of surgical procedures being performed, changing lifestyles, and increasing incidences of cancer are some of the factors driving growth in the pain management sector.
Achnil has received an overwhelming response from the market within a few months of its market launch. The product has proved to be a boom in the acute-to-chronic pain management space and has the capability to turn out to be an illustrious product. Reduction in post-surgical adhesions has been the most welcomed effect by the medical fraternity. On the future plans, Dr Manu Chaudhary says, "Having attained a patent grant from Europe, we are planning to launch the product in Europe by extending exclusive marketing rights to a competent partner having marketing muscles in Europe and the US.
Profiles of other winners